NuScale Power Down 35% YTD: Is It a Buy-the-Dip Opportunity?

NuScale Power has fallen 23% in the past month and 34.5% year to date, with first-quarter revenue of only about $565,000 against a net loss of roughly $44 million. The article argues the stock is still speculative despite its NRC-approved SMR design, as commercialization remains unproven and execution, financing and dilution risks persist. Analysts still model 37% 2026 revenue growth and 355% growth in 2027, but from a very small base; the stock is rated Zacks Rank #3 (Hold).

Analysis

The market is treating the entire advanced-nuclear basket as one factor trade, but the reaction function is different underneath the hood. SMR’s regulatory lead gives it the best probability of eventual commercialization, yet that advantage is not monetizable until a first contract turns into financed steel in the ground; until then, the stock is effectively a long-duration call option on project finance, not on near-term earnings.

The second-order winner from AI/data-center power demand may not be the reactor vendors themselves, but the ecosystem that can underwrite balance-sheet risk: engineering firms, EPC partners, uranium conversion/enrichment, and grid/interconnection specialists. If hyperscalers decide they need firm power in the next 24-36 months, the market will likely prefer smaller, modular deployments with clearer financing paths over bespoke first-of-a-kind projects, which is a relative positive for OKLO/NNE only if they can de-risk fuel and siting faster than SMR can close a contract.

The key risk is not technical feasibility; it is timeline slippage plus equity dilution. In this setup, a 6-12 month delay can be as damaging as a permanent loss of competitiveness because the company may need to fund continued pre-revenue burn into a weak equity tape. That makes upside path-dependent: a signed customer agreement, project financing, or sovereign-backed international approval would likely trigger a sharp re-rating, but absent that, rallies are vulnerable to being sold into.

Consensus may be underestimating how quickly the stock can re-rate on one credible commercialization headline, but it is also likely overestimating the optionality embedded in current valuation. The stock is not cheap on any operating basis; it is only cheap relative to prior enthusiasm. That argues for trading around catalysts rather than owning passively through the commercialization gap.

Key Decisions for Investors

• Avoid outright long SMR here; if expressing bullish exposure, use a 3-6 month call spread instead of stock to cap dilution and timing risk. Target a contract/financing headline as the catalyst; risk/reward is favorable only if entry is priced as a volatility bet, not an earnings multiple.
• Pair trade: long SMR / short a basket of weaker advanced-nuclear peers on any confirmation headline, but keep sizing small. SMR has the cleaner regulatory path, so it should outperform first on a de-risking event even if the group rallies together.
• For tactical longs, wait for a firm order or project-finance milestone; buy only after confirmation, not on speculation. The setup is better for momentum follow-through over 1-4 weeks after a headline than for pre-event accumulation.
• Use OKLO and NNE as relative-value shorts versus SMR only if the market starts rewarding regulatory certainty over moonshot optionality. The trade works best if investors rotate from narrative to execution over the next 1-3 months.
• Set downside alerts on SMR for any follow-on equity financing language; if capital raise risk rises, expect another 15-25% drawdown as the market prices in dilution before revenue visibility improves.